We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+30.09%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$238M
AUM Growth
-$14.5M
Cap. Flow
-$47.8M
Cap. Flow %
-20.06%
Top 10 Hldgs %
75.28%
Holding
38
New
2
Increased
10
Reduced
3
Closed
13

Top Buys

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$8.18M
2
ADMS
Adamas Pharmaceuticals
ADMS
+$5.51M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$5.19M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.45M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$3.84M

Top Sells

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$22M
2
DYAX
DYAX CORPORATION
DYAX
+$14.3M
3
RLYP
RELYPSA INC COM
RLYP
+$14.2M
4
MDCO
Medicines Co
MDCO
+$5.69M
5
STML
Stemline Therapeutics, Inc.
STML
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 58.12%
2 Technology 6.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
1
DELISTED
Adamas Pharmaceuticals
ADMS
$40.7M 17.08%
1,437,335
+327,335
+29% +$5.51M
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$23.6M 9.92%
569,658
-657,127
-54% -$22M
ZGNX
3
DELISTED
Zogenix, Inc.
ZGNX
$20.9M 8.75%
1,414,927
+52,164
+4% +$701K
VNDA icon
4
Vanda Pharmaceuticals
VNDA
$307M
$19.6M 8.2%
2,100,101
+385,101
+22% +$3.84M
TTPH
5
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$19.5M 8.17%
97,000
+41,000
+73% +$8.18M
CNXR
6
DELISTED
Connecture, Inc.
CNXR
$14.9M 6.25%
4,127,232
– –
ARCT icon
7
Arcturus Therapeutics
ARCT
$164M
$12.6M 5.3%
287,517
+115,348
+67% +$5.19M
EXEL icon
8
Exelixis
EXEL
$13.3B
$11.5M 4.81%
2,032,494
+442,494
+28% +$2.48M
SGYP
9
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$8.77M 3.68%
1,546,888
+411,308
+36% +$2.51M
VIRX
10
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.4M 3.11%
39,286
+23,810
+154% +$4.45M
GWPH
11
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.94M 2.91%
100,000
– –
PRTK
12
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.74M 2.83%
355,459
-98,419
-22% -$1.88M
RPTP
13
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$6.67M 2.8%
1,282,527
-52,473
-4% -$304K
AUPH icon
14
Aurinia Pharmaceuticals
AUPH
$1.91B
$6.16M 2.59%
2,457,144
– –
OCRX
15
DELISTED
Ocera Therapeutics, Inc.
OCRX
$6.13M 2.57%
1,963,777
– –
APYX icon
16
Apyx Medical
APYX
$173M
$5.63M 2.36%
2,680,000
– –
VCEL icon
17
Vericel Corp
VCEL
$2.35B
$5.38M 2.26%
2,086,028
– –
ARDM
18
DELISTED
Aradigm Corp Common Stock
ARDM
$3.98M 1.67%
1,002,962
– –
TENX icon
19
Tenax Therapeutics
TENX
$363M
$3.64M 1.53%
35
– –
LSTA icon
20
Lisata Therapeutics
LSTA
$9.02M
$2.43M 1.02%
14,992
– –
TTHI
21
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$1.65M 0.69%
856,602
+409,576
+92% +$778K
FLXN
22
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.5M 0.63%
78,100
+11,800
+18% +$205K
CYTK icon
23
PUT
Cytokinetics
CYTK
$10.5B
$1.12M 0.47%
+106,800
New +$1.05M
MNKD icon
24
PUT
MannKind Corp
MNKD
$1.21B
$729K 0.31%
+100,600
New +$1.24M
STRM
25
DELISTED
Streamline Health Solutions
STRM
$214K 0.09%
10,107
– –
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2015 Portfolio in Review

As of Q4 2015, Great Point Partners held 38 positions worth $238M, down 5.7% from $253M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Great Point Partners withdrew a net $47.8M in Q4 2015, closing 13 positions and reducing 3 holdings. Its most notable exit was DYAX CORPORATION, an estimated $14.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 54% a quarter earlier, followed by Technology.

Against the trend, Great Point Partners added an estimated $8.18M to Tetraphase Pharmaceuticals, Inc..

  • Great Point Partners added most to Tetraphase Pharmaceuticals, Inc. in Q4 2015, an estimated $8.18M increase.
  • Great Point Partners's biggest Q4 2015 reduction was Five Prime Therapeutics, Inc., cutting an estimated $22M.
  • Great Point Partners fully exited DYAX CORPORATION in Q4 2015, selling an estimated $14.3M.
  • Great Point Partners's ten largest holdings make up 75% of its $238M portfolio in Q4 2015.
  • Great Point Partners opened 2 new positions and closed 13 in Q4 2015.
  • Great Point Partners's portfolio value fell 5.7% quarter-over-quarter to $238M.

Based on Great Point Partners's 13F filing for Q4 2015, filed 16 Feb 2016.